Replies to post #40130 on Biotech Values

[Gametheory101]

..."The gutting of DNDN's pipeline due to halting all work on everything but the Provenge BLA, no early-stage PCa trials on the horizon for Provenge, and two financings at $4.50 are perfect examples of why management teams should partner their first drugs even if the deals are not perfect"...


Amgen has wished for years that they had taken the Dendreon route, rather than the poor partenrship deal they signed with Johnson and Johnson that has cost them billions in revenue.

Based on the pummeling of AGIX shares even with a partnership in hand, then who is to say what the price per share of DNDN would have done the last two years with a poor partnership deal in hand? Especially since no matter what good news Dendreon releases, the stock faces unrelenting shorting and selling.